Semaglutide for Alcohol Addiction: Phase 3 Study 2026

Denmark: A Danish Phase 3 study published in The Lancet (April 2026) demonstrates that Semaglutide significantly reduces heavy drinking days in individuals with alcohol use disorder (AUD) and obesity. The results show that this GLP-1 receptor agonist, primarily known for weight management, offers a highly effective pharmacological perspective for treating alcohol dependence.

Key Findings on Semaglutide for Alcohol Use Disorder

• Semaglutide (2.4 mg/week) reduced heavy drinking days by 41.1 percentage points over 26 weeks, outperforming placebo by 13.7 points (p=0.0015).
• The Number Needed to Treat (NNT) was 4.3, which indicates high clinical efficacy for AUD patients.
• All 108 participants received 10 sessions of cognitive behavioral therapy alongside the medication.
• The study successfully bridges the gap between preclinical evidence and clinical application for GLP-1 agonists in addiction treatment.

How Was the Danish Phase 3 Study on Semaglutide Structured?

The study by Klausen et al. (2026)^[1] is the largest randomized, placebo-controlled Phase 3 trial to date investigating Semaglutide for alcohol use disorder. It involved 108 adults seeking treatment for moderate to severe AUD and obesity (BMI ≥30 kg/m²). Participants received either 2.4 mg of Semaglutide or a placebo once weekly for 26 weeks, combined with standardized cognitive behavioral therapy. The primary endpoint measured the percentage reduction in heavy drinking days, defined as consuming ≥48 g of alcohol for women and ≥60 g for men.

How Strong Was the Effect of Semaglutide on Drinking Behavior?

Semaglutide treatment resulted in a 41.1 percentage point reduction in heavy drinking days, which was 13.7 points more than the placebo group (p=0.0015)^[5]. With a Number Needed to Treat (NNT) of 4.3, approximately one in four patients experiences a clinically significant benefit, making Semaglutide more effective than currently approved AUD medications^[8]. Secondary outcomes also showed improvements in total alcohol consumption, alcohol-free days, craving levels, liver values, and metabolic markers like body weight and HbA1c^[10].

What Does This Mean for the Future of Addiction Medicine?

This study provides the first robust clinical evidence that GLP-1 receptor agonists like Semaglutide can effectively reduce alcohol consumption, addressing a global health issue responsible for 5% of deaths worldwide^[5]. The authors highlight that these results confirm earlier preclinical findings and position Semaglutide as a potential new standard for AUD treatment^[7]. However, since the study population was predominantly white and obese, further research is needed to generalize these findings to more diverse patient groups^[10].

What Is the Current State of Evidence for GLP-1 Agonists?

The evidence for using GLP-1 agonists in AUD is transitioning from anecdotal reports to controlled clinical data, supported by a systematic review in the European Journal of Medical Research (July 2026). While the Lancet study is a major milestone, the medical community still requires more research with longer follow-up periods. Future studies must focus on long-term safety and efficacy across diverse populations to fully establish GLP-1 agonists as a pillar of addiction therapy.

Important Medical Disclaimer

Note: This article is for informational purposes only and does not replace professional medical advice. If you have questions about your health or alcohol consumption, please consult a doctor.